Abstract
In this study, the effects of nine alpha-1 adrenoceptor antagonists [prazosin, WB 4101 (WB), chloroethylclonidine (CEC), 5-methylurapidil (5-MU), BMY 7378 (BMY), MDL 73005EF (MDL73), MDL 72832 (MDL72), RS 17053 (RS) and SK&F 105854 (SKF)] were studied on contractile responses to phenylephrine (PE) of the endothelium-denuded dog aorta in vitro. All antagonists, except CEC, 5-MU and RS, produced concentration-dependent competitive inhibition of contractile responses of the aorta to PE. The rightward shift of the concentration-response curves of PE yielded constant pKBvalues with increasing antagonist concentrations in most cases allowing a single pooled value to be determined: for prazosin, a pKBof 8.99 ± 0.11 (n = 20,KB of 1.03 nM); for WB, a pKB of 8.75 ± 0.08 (n = 23,KB of 1.76 nM); for BMY, a pKBof 7.21 ± 0.13 (n = 13,KB of 62 nM); for MDL72, a pKBof 7.95 ± 0.15 (n = 12,KB of 11.2 nM); and for SK&F 105854, a pKB of 5.82 ± 0.08 (n = 15,KB of 1.52 μM). For MDL73, pKBvalues decreased with antagonist concentration: 7.88 ± 0.06 at 10 nM, 7.56 ± 0.28 at 100 nM and 6.92 ± 0.18 at 1000 nM, which suggests the presence of more than one receptor subtype. CEC (10 and 100 μM) almost completely inhibited responses to PE; lower concentrations had no significant effect. 5-MU (10–300 nM) and RS (3–300 nM) were ineffective antagonists in this tissue. Because WB, a highly selective alpha-1D andalpha-1A adrenoceptor subtypes inhibitor, blocked PE responses (with less affinity than foralpha-1A adrenoceptors), and 5-MU and RS, which are selective blockers for alpha-1A adrenoceptor, were ineffective, we conclude that alpha-1A adrenoceptors are absent in the dog aorta. The effects of the less selective MDL72 were inconsistent with actions at alpha-1B oralpha-1D adrenoceptors. Although WB shifted the PE concentration-response curve to the right, the abilities of BMY, MDL73 and SKF to inhibit competitively PE contraction were of lower affinity compared with expectations for interaction with alpha-1D adrenoceptors; they are not the predominant subtype. The complete inhibition of PE responses by CEC suggests that the dog aorta contains the alpha-1B adrenoceptor subtype. In immunocytochemical studies of the expression of alpha-1B adrenoceptor, all cells apparently expressed this protein. Moreover, Western blot studies of the microsomal fractions confirmed the presence ofalpha-1B adrenoceptors. In the dog aorta, the alpha-1 adrenoceptors predominantly resemblealpha-1B rather than alpha-1D adrenoceptors as reported in the rat aorta.
Footnotes
-
Send reprint requests to: E.E. Daniel, PhD, Professor Emeritus, Room 4N51, Department of Biomedical Sciences, McMaster University, Hamilton ON L8N 3Z5, Canada.
-
↵1 Supported by the Heart and Stroke Foundation of Ontario.
-
↵2 Recipient of the Career Investigator award of the Heart and Stroke Foundation of Ontario.
- Abbreviations:
- BMY
- BMY 7378 or {8-(2-[4-(2-methoxyphenyl)-1-piperazinyl]-ethyl)- 8-azaspirol[4,5]decane-7,9-dione
- Bmax
- maximum concentration of bound ligand per mg membrane protein
- CEC
- chloroethylclonidine
- DMA
- dog mesenteric artery
- EC50
- concentration for 50% maximum response
- IC50
- 50% inhibitory concentration
- KB
- calculated antagonist dissociation constant in functional studies
- KD
- dissociation constant in saturation ligand binding studies
- Ki
- dissociation constant in competition ligand binding studies
- MDL72
- MDL 72832, {8-[4-(1,4-benzodioxan-2-ylmethylamino)butyl]-8-azaspirol[4,5]decane-7,9-dione HCl
- MDL73
- MDL 73005EF, {8-[2-(1,4-benzodioxan-2-ylmethylamino)ethyl]-8-azaspirol[4,5]decane-7,9-dione HCl
- MIC2
- microsomal fraction used for binding
- RS
- RS-17053 or N-[2-(-cyclopropyl methoxy phenoxy) ethyl]-5-chloro-α, α-dimethyl-1H-indole-3-ethanamine HCl
- SKF
- SK&F 105854 or 7-chloro-2-bromo-3,4,5,6-tetrahydro-4-methylfurol[4,3,2-ef]-3 benzapine
- WB
- WB 4101 or 2-(2,6-dimethoxyphenoxyethyl)-aminomethyl-1,4-benzodioxane
- 5-MU
- 5-methylurapidil
- PE
- phenylephrine
- Received August 21, 1997.
- Accepted January 30, 1998.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|